What STEP-1 Actually Changes in Clinical Practice

At a glance

| Parameter | Detail | |---|---| | N | 1,961 (semaglutide 1,306; placebo 655) | | Intervention | Semaglutide 2.4 mg subcutaneous, once weekly | | Comparator | Matched placebo injection + lifestyle intervention | | Duration | 68 weeks | | Primary endpoint | Percent change in body weight from baseline | | Key result | −14.9% (semaglutide) vs −2.4% (placebo); estimated treatment difference −12.4 percentage points (P<0.001) | | Registration | NCT03548935 |

Why the Abstract Undersells This Trial

Most summaries of STEP-1 stop at the headline: 14.9% weight loss, well above placebo. That number matters, but the clinical meaning sits in three layers beneath it.

First, a third of participants lost ≥20% of body weight. That threshold had previously been associated almost exclusively with bariatric surgery. Second, the weight-loss curve had not fully plateaued at week 68 for a meaningful subset of responders, suggesting the 14.9% average may understate the drug's ceiling in longer treatment windows. Third, every pre-specified cardiometabolic secondary endpoint moved in the right direction: waist circumference (−13.54 cm vs −4.13 cm), systolic blood pressure, C-reactive protein, and fasting lipids all improved significantly in the semaglutide group.

These secondary signals, combined with the weight-loss magnitude, gave downstream trials (STEP-HFpEF, SELECT) a biological rationale to test cardiovascular and heart-failure outcomes directly.

Methodology Notes That Change How You Read the Data

The lifestyle backbone was real

Both arms received a structured lifestyle intervention: 150 minutes of physical activity per week plus a 500 kcal/day deficit diet, delivered through 18 individual counseling sessions. This was not a "usual care" comparator. The placebo arm's 2.4% weight loss confirms that counseling alone produced measurable (though modest) results. The treatment difference is therefore additive to an already-active control, not additive to doing nothing.

Dose escalation masked early tolerability

Participants started at 0.25 mg weekly and escalated every four weeks, reaching the target 2.4 mg dose by week 16. Nausea, the most common adverse event (44.2% semaglutide vs 17.4% placebo), was concentrated during escalation. By steady-state dosing, most GI symptoms had attenuated. Clinicians who see patients abandon GLP-1 agonists in the first month should note this: the trial protocol tolerated early nausea as transient, and the completion rate (86.1% in the semaglutide arm) supports that patience.

The "treatment policy" estimand matters

STEP-1 used two statistical estimands. The treatment-policy estimand (the primary one) included all randomized participants regardless of whether they stayed on drug. The trial-product estimand, which censored data after treatment discontinuation, showed −15.3% weight loss. The gap between these two numbers is small, which means discontinuation did not heavily dilute the result. This is unusual for obesity trials, where dropout rates historically erode intention-to-treat effect sizes.

The HealthRX.com Practice-Translation Framework

We score every obesity-pharmacotherapy trial on five axes that matter for real-world prescribing. This framework is original to the HealthRX.com Medical Team.

| Axis | STEP-1 Score | Rationale | |---|---|---| | Effect magnitude | 5/5 | −14.9% mean; ≥20% loss in 32% of patients | | Durability signal | 3/5 | No plateau at 68 wk, but STEP-1 Extension showed regain after stopping | | Tolerability | 4/5 | 86.1% completion; GI AEs transient in most; 7% discontinued for AEs | | Population match | 3/5 | BMI ≥30 (or ≥27 + comorbidity), no T2D; excludes a large prescribing population | | Guideline adoption | 5/5 | Directly cited in AGA 2022, Endocrine Society 2024, AAP 2023 updates |

Total: 20/25. Strong enough to anchor a first-line pharmacotherapy conversation in patients without type 2 diabetes, but the durability gap (weight regain on cessation) and exclusion of patients with diabetes limit the score.

Which Guidelines Actually Changed

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity lists semaglutide 2.4 mg as a first-line option alongside tirzepatide for adults with BMI ≥30 or BMI ≥27 with weight-related complications. STEP-1 is cited as the principal efficacy evidence for this recommendation.

The American Gastroenterological Association's 2022 clinical practice guideline similarly elevated GLP-1 receptor agonists above older agents (phentermine, orlistat) on the strength of the STEP program's effect sizes.

Before STEP-1, most society guidelines treated anti-obesity medications as adjuncts to be tried briefly and discontinued if results were modest. After STEP-1, the framing shifted: pharmacotherapy became a chronic-disease intervention, analogous to statins for hyperlipidemia, where stopping the drug meant losing the benefit.

What Changed in Prescribing Patterns

Three prescribing shifts trace directly to STEP-1 data.

Longer treatment horizons. Prior obesity drugs were often prescribed in 3-to-6 month courses. STEP-1's 68-week design, paired with post-hoc data showing continued trajectory at that mark, pushed formulary committees toward open-ended authorization. The Wegovy prescribing information does not specify a treatment-stop date.

Higher BMI thresholds for insurance coverage dropped. Before 2021, many U.S. payers required BMI ≥40 (or ≥35 + comorbidities) for anti-obesity medication coverage. STEP-1 enrolled participants at BMI ≥30 without comorbidity requirements, and payer policies gradually aligned with this lower threshold after FDA approval of Wegovy in June 2021.

Cardiometabolic co-prescribing. Clinicians began prescribing semaglutide 2.4 mg not only for weight loss per se but with explicit cardiometabolic targets in mind. The SELECT trial (Lincoff et al., 2023) later validated this instinct by showing a 20% reduction in major adverse cardiovascular events, but STEP-1's secondary endpoints had already pointed prescribers in that direction.

Patients Who Don't Match the Trial Population

STEP-1 excluded several groups that make up a large share of real-world obesity referrals.

Patients with type 2 diabetes. STEP-2 addressed this population separately, with a smaller mean weight loss (−9.6%). Clinicians should not extrapolate the 14.9% figure to patients on metformin, SGLT2 inhibitors, or insulin. The metabolic environment in type 2 diabetes blunts GLP-1-mediated weight loss, likely because of overlapping incretin pathways already partially activated by endogenous or exogenous therapies.

Patients on other weight-affecting medications. Antipsychotics, corticosteroids, and certain antidepressants were exclusion criteria or confounders. A patient gaining weight on olanzapine faces a different physiological problem than STEP-1's cohort, and the trial cannot speak to whether semaglutide overcomes drug-induced weight gain at the same magnitude.

Adolescents. STEP TEENS later showed efficacy in ages 12 to 17, but the dose-response and safety profile in younger patients required its own trial. STEP-1 data should not be presented to families as directly applicable.

BMI 25 to 27 range. STEP-1's lower BMI cutoff was 27 (with a comorbidity) or 30 (without). A growing off-label interest in semaglutide for "cosmetic" weight loss in people with BMI 25 to 27 has no support from this trial's enrollment criteria or subgroup analyses.

Limitations the Authors Acknowledged

The original publication lists several limitations worth repeating because they affect clinical translation.

The trial population was 75% female and 75% White. Efficacy and tolerability data in men and in Black, Hispanic, and Asian populations are thinner. Subgroup analyses by race and sex did not show statistically significant interaction effects, but these subgroups were underpowered for that purpose.

The lifestyle intervention backbone (500 kcal deficit, 150 min/wk activity, 18 counseling sessions) is not reproducible in most primary care settings. Patients receiving semaglutide without structured counseling may see different results, though the direction of the effect is unlikely to reverse.

No data exist beyond 68 weeks from STEP-1 itself. The STEP-1 Extension study showed that participants who stopped semaglutide at week 68 regained approximately two-thirds of lost weight by week 120. This makes the trial a strong argument for efficacy and a weaker argument for cure.

The Durability Problem

Weight regain after discontinuation is the single most important caveat in translating STEP-1 to practice. The STEP-1 Extension data (Wilding et al., 2022) showed that within one year of stopping semaglutide, participants regained an average of 11.6 percentage points of the 17.3% they had lost (in the trial-product estimand population).

This pattern is consistent across anti-obesity medications and mirrors what happens when antihypertensives or statins are stopped. The clinical implication is straightforward: if you start semaglutide 2.4 mg for obesity, plan for indefinite treatment. Prescribers who frame the drug as a short-term "kickstart" are misreading both the trial evidence and the biology of adiposity set-point regulation.

What STEP-1 Does Not Answer

Several questions remain open even after the full STEP program.

Can lower maintenance doses preserve weight loss with fewer side effects? No STEP trial tested dose de-escalation after reaching target weight. Some clinicians prescribe 1.0 mg or 1.7 mg as maintenance; this practice has no controlled evidence behind it.

Does semaglutide 2.4 mg reduce all-cause mortality? SELECT showed cardiovascular event reduction, but mortality data remain statistically inconclusive at published follow-up durations.

How does semaglutide compare head-to-head with tirzepatide? The SURMOUNT trials showed larger weight-loss numbers for tirzepatide (−20.9% at the highest dose), but no direct randomized comparison exists. Indirect comparisons across trials are unreliable given differences in populations, lifestyle interventions, and endpoint definitions.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
2. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
4. Wegovy (semaglutide) prescribing information. Novo Nordisk. Revised 2023. FDA Label
5. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effect of semaglutide 2.4 mg in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083-2091. PubMed
6. Amaro A, Sugimoto D, Cusi K. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(10):2655-2680. PubMed